CANADA LIFE ASSURANCE Co Purchases 13,563 Shares of Illumina, Inc. (NASDAQ:ILMN)

CANADA LIFE ASSURANCE Co raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 5.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 279,836 shares of the life sciences company's stock after acquiring an additional 13,563 shares during the quarter. CANADA LIFE ASSURANCE Co owned approximately 0.18% of Illumina worth $37,382,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. XTX Topco Ltd bought a new position in Illumina in the third quarter valued at $226,000. M&T Bank Corp grew its holdings in shares of Illumina by 3.4% in the 3rd quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company's stock valued at $7,091,000 after acquiring an additional 1,769 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Illumina in the third quarter valued at about $772,000. Tidal Investments LLC raised its holdings in Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company's stock worth $580,000 after acquiring an additional 1,226 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its position in Illumina by 66.8% during the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company's stock valued at $1,582,000 after purchasing an additional 4,797 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 3.2 %

Shares of Illumina stock opened at $71.21 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a market capitalization of $11.27 billion, a price-to-earnings ratio of -9.27, a PEG ratio of 1.60 and a beta of 1.38. The firm's 50-day moving average price is $84.61 and its two-hundred day moving average price is $120.40.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ILMN. Piper Sandler upped their price objective on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Stephens reaffirmed an "overweight" rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. HSBC downgraded shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, Guggenheim reduced their price target on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.